SYSTM Wealth Solutions LLC Has $2.50 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

SYSTM Wealth Solutions LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 42.2% in the 1st quarter, HoldingsChannel reports. The fund owned 10,088 shares of the medical instruments supplier’s stock after selling 7,351 shares during the period. SYSTM Wealth Solutions LLC’s holdings in Becton, Dickinson and Company were worth $2,497,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Journey Strategic Wealth LLC raised its holdings in Becton, Dickinson and Company by 4.3% in the 1st quarter. Journey Strategic Wealth LLC now owns 1,776 shares of the medical instruments supplier’s stock valued at $439,000 after acquiring an additional 74 shares in the last quarter. Rathbones Group PLC raised its holdings in Becton, Dickinson and Company by 3.5% in the 1st quarter. Rathbones Group PLC now owns 125,604 shares of the medical instruments supplier’s stock valued at $31,092,000 after acquiring an additional 4,274 shares in the last quarter. Taylor Hoffman Wealth Management raised its holdings in Becton, Dickinson and Company by 4.8% in the 1st quarter. Taylor Hoffman Wealth Management now owns 1,087 shares of the medical instruments supplier’s stock valued at $269,000 after acquiring an additional 50 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Becton, Dickinson and Company by 0.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,437,363 shares of the medical instruments supplier’s stock valued at $355,805,000 after acquiring an additional 7,566 shares in the last quarter. Finally, Buckhead Capital Management LLC raised its holdings in shares of Becton, Dickinson and Company by 10.8% in the 1st quarter. Buckhead Capital Management LLC now owns 38,352 shares of the medical instruments supplier’s stock worth $9,494,000 after buying an additional 3,741 shares in the last quarter. Institutional investors and hedge funds own 86.72% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE BDX traded down $1.75 during trading hours on Wednesday, reaching $279.72. 475,726 shares of the company’s stock were exchanged, compared to its average volume of 1,153,096. The stock has a market cap of $81.15 billion, a PE ratio of 51.08, a price-to-earnings-growth ratio of 2.33 and a beta of 0.57. Becton, Dickinson and Company has a one year low of $215.90 and a one year high of $287.32. The firm has a fifty day moving average of $269.57 and a 200-day moving average of $255.37. The company has a current ratio of 1.25, a quick ratio of 0.73 and a debt-to-equity ratio of 0.58.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.96 EPS for the quarter, beating the consensus estimate of $2.89 by $0.07. The company had revenue of $4.88 billion during the quarter, compared to analysts’ expectations of $4.84 billion. Becton, Dickinson and Company had a return on equity of 13.24% and a net margin of 8.73%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period last year, the firm earned $2.66 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 12.23 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.91 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $3.64 annualized dividend and a dividend yield of 1.30%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 66.06%.

Insider Activity

In other news, Director Claire Fraser sold 848 shares of Becton, Dickinson and Company stock in a transaction on Monday, August 28th. The stock was sold at an average price of $281.66, for a total value of $238,847.68. Following the completion of the sale, the director now directly owns 21,608 shares of the company’s stock, valued at approximately $6,086,109.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Claire Fraser sold 848 shares of Becton, Dickinson and Company stock in a transaction on Monday, August 28th. The stock was sold at an average price of $281.66, for a total transaction of $238,847.68. Following the completion of the sale, the director now directly owns 21,608 shares of the company’s stock, valued at $6,086,109.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,300 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $277.13, for a total value of $360,269.00. Following the sale, the executive vice president now directly owns 5,157 shares of the company’s stock, valued at $1,429,159.41. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,122 shares of company stock valued at $1,425,443. Company insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of a number of recent research reports. Morgan Stanley increased their target price on Becton, Dickinson and Company from $295.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, August 4th. Raymond James dropped their target price on Becton, Dickinson and Company from $305.00 to $304.00 and set an “outperform” rating for the company in a report on Friday, August 4th. Piper Sandler increased their target price on Becton, Dickinson and Company from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, July 24th. Citigroup increased their target price on Becton, Dickinson and Company from $260.00 to $282.00 and gave the stock a “neutral” rating in a report on Monday, August 21st. Finally, StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, August 16th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $288.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.